Coxsackievirus B3 infection compromises endothelial-dependent vasodilation of coronary resistance arteries

Jonathan C Choy1, Amy H Lui, Farzad Moien-Afshari

  • 1UBC McDonald Research Laboratories/The iCAPTUR4E Centre, Department of Pathology and Laboratory Medicine, St. Paul's Hospital/Providence Health Care-University of British Columbia, British Columbia, Canada.

Insights

Coxsackievirus B3 (CVB3) infection impairs coronary artery function in viral myocarditis. Late-stage CVB3 infection reduces acetylcholine-induced vasodilation, suggesting endothelial dysfunction not linked to ET-1 but possibly reduced nitric oxide secretion.

Area of Science:

  • Cardiovascular Research
  • Virology
  • Immunology

Background:

  • Viral myocarditis, often caused by Coxsackievirus B3 (CVB3), can lead to coronary artery dysfunction.
  • The precise mechanisms underlying CVB3-mediated vascular dysfunction remain incompletely understood.

Purpose of the Study:

  • To investigate the early and late effects of CVB3 infection on coronary artery function using pressure myography.
  • To determine the role of endothelin-1 (ET-1) and endothelial nitric oxide (NO) secretion in CVB3-induced vascular dysfunction.

Main Methods:

  • Male CD-1 mice were infected with CVB3 or PBS (sham control).
  • Coronary septal arteries were analyzed using pressure myography at 3, 7, and 42 days post-infection.
  • Vascular responses to pressure, agonists (acetylcholine), and smooth muscle stimulators (KCl, sodium nitroprusside) were assessed.
  • ET-1 levels, viral presence, and cell death were evaluated via immunohistochemistry, immunoassay, in situ hybridization, and TUNEL staining.

Main Results:

  • CVB3 infection did not alter pressure-induced myogenic tone or smooth muscle function at early or late time points.
  • Agonist-induced vasodilation to acetylcholine was significantly reduced at 42 days post-infection.
  • ET-1 antagonism did not fully restore vasodilation, and ET-1 levels were unchanged, excluding its direct role.
  • No viral presence or cell death was detected in the coronary artery endothelium.

Conclusions:

  • Late-stage CVB3 infection impairs endothelial-dependent vasorelaxation in coronary resistance vessels.
  • This dysfunction is not mediated by altered ET-1 expression.
  • The findings suggest that decreased stimulated nitric oxide secretion by the endothelium may underlie the observed vascular impairment in CVB3-induced myocarditis.

Related Concept Videos

Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...